alexa RNAdjuvant?: A Novel, Highly-potent, RNA-based Adjuvant For Prophylactic And Therapeutic Vaccines
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Regina Heidenreich, Benjamin Petsch, Mariola Fotin-Mleczek, Patrick Baumhof, Birgit Scheel, S?hnke Voss, Edith Jasny, Thomas Kramps and Karl-Josef Kallen
Posters: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.017
Abstract
G iven the important role of adjuvants in prophylactic vaccines as well as tumor immunotherapy, identification and development of new adjuvants with enhanced efficacy and safety is necessary. CureVac has recently developed a novel RNA- based adjuvant with strong immunostimulatory properties. RNAdjuvant? is physically and chemically well-defined and exhibits a very good safety profile. RNAdjuvant? is well tolerated even at high doses and does not induce splenomegaly in mice as described for standard adjuvants such as CpG-DNA. In vitro , RNAdjuvant? induced activation of APC leading to an increased expression of specific activation markers and secretion of cytokines driving a pronounced Th1 response. In vivo , RNAdjuvant? boosted even very immunogenic influenza vaccines inducing balanced Th1/Th2 T cell responses. Vaccination with RNAdjuvant? accelerated onset of protective antibody responses to approved influenza vaccines, enhanced vaccine specific T cell responses and enabled significant dose sparing. In addition, RNAdjuvant? combined with human papillomavirus (HPV)-derived recombinant peptides elicited strong antigen-specific cytotoxic T-cell responses, which are barely induced by vaccination with peptide alone. Vaccination with RNAdjuvant? with HPV-derived peptides mediated complete tumor protection in a prophylactic setting, as well as significant growth inhibition of already established tumors after therapeutic vaccination. Taken together our data demonstrate that RNAdjuvant? represents a novel breakthrough technology that can be combined with almost any type of antigen that requires safe and potent adjuvants.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords